Concepedia

Gontran Verset

GV

Statistics

Publications

25

Citations

5.6K

H-Index

19

Active since

2004

Affiliations

Erasmus Hospital(Current)

Université Libre de Bruxelles

National Taiwan University Hospital

Massachusetts General Hospital

Chinese University of Hong Kong

Gontran Verset is an author at Erasmus Hospital specializing in medicine, oncology, and hepatocellular carcinoma treatment.

ORCID

Publications per year

2004–2025

25

Publications

25

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

, , +11

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Christophe Van Steenkiste, Gontran Verset · The Lancet · 2023 · 679 citations

, , +12

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng et al. · The Lancet Oncology · 2022 · 522 citations · Full text

, , +17

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

, , +14

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Thomas Yau, Peter R. Galle, Thomas Decaens et al. · The Lancet · 2025 · 270 citations · Full text

, , +15

1–5 of 25